Changes in 652d728: add clinical section

				EZH2.md
			
          @@ -18,7 +18,7 @@ Although mutations in EZH2 have been described in some BL patients, they are ext

           Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011]

          -## Clinical relevance

          +## Clinical Relevance

           A number of small molecule/pharmacologic inhibitors of EZH2 activity have been described.[@garapaty-raoIdentificationEZH2EZH12013; @knutsonSelectiveInhibitionEZH22014] At least one of these, tazemetostat, has shown benefit in FL.[@morinTreatingLymphomaNow2021] Tazemetostat (TAZVERIK) has [FDA approval](https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma) *for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options.* Combination therapies including EZH2 inhibitors are also under exploration for DLBCL patients with mutant EZH2.[@scholzeCombinedEZH2Bcl22020]

...	...	@@ -18,7 +18,7 @@ Although mutations in EZH2 have been described in some BL patients, they are ext
18	18
19	19	Mutations at the main hotspot and some less common hotspots lead to enhanced methylation by PRC2.[@yapSomaticMutationsEZH22011]
20	20
21		-## Clinical relevance
	21	+## Clinical Relevance
22	22
23	23	A number of small molecule/pharmacologic inhibitors of EZH2 activity have been described.[@garapaty-raoIdentificationEZH2EZH12013; @knutsonSelectiveInhibitionEZH22014] At least one of these, tazemetostat, has shown benefit in FL.[@morinTreatingLymphomaNow2021] Tazemetostat (TAZVERIK) has [FDA approval](https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma) for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. Combination therapies including EZH2 inhibitors are also under exploration for DLBCL patients with mutant EZH2.[@scholzeCombinedEZH2Bcl22020]
24	24